Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
In a phase II trial of moderate-to-severe major depressive disorder, 6 weeks of intensive treatment with psilocybin or ...
After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...
Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...
Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...
Studies showed Bristol Myers Squibb's drug, KarXT, improved symptoms of schizophrenia and led to fewer side effects than existing antipsychotic treatments. Researchers are optimistic patients might ...
Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer ...
As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback